Alvotech Marks Denosumab Milestone

AVT03 Proposed Biosimilar To Prolia/Xgeva Passes PK Study; Further Trials Ongoing

 
• By David Wallace
  
Alvotech’s AVT03 denosumab candidate has passed a PK study
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Biosimilars

More from Products